CDC vaccine advisors endorse Pfizer, Moderna COVID boosters for all adults Merck pauses 'very important' HIV program after seeing red flag in phase 2 trial of once-weekly combo Here are the policies and reforms that could reshape healthcare in the $2T bill just passed by the House Biden's Medicare drug price negotiations will leave pharma mostly unscathed: CBO Healthcare associations, experts urge employers to swiftly adopt OSHA's 'commonsense' vaccination requirements Roche launches more compact cobas 5800 analyzer for smaller European diagnostic labs FDA asks for 55 years to complete FOIA request on Pfizer's COVID-19 vaccine BMS heart drug, center of its $13B MyoKardia buyout, hit by FDA delay Enanta dumps oral hep B program after safety warnings in early test BioMarin's dwarfism drug Voxzogo could be its next blockbuster, but ethics questions loom over the launch Nursing startup nabs $149M for healthcare staffing platform Cloud R&D developer Benchling picks up second nine-figure venture capital haul this year New insights into how cancer cripples immune cells could fuel fresh I-O approaches Featured Story | By Kevin Dunleavy A CDC advisory committee of vaccine experts has signed off on allowing adults age 18 and older to receive a COVID-19 booster shot with the Moderna or Pfizer-BioNTech vaccine. With final approval from CDC director Rochelle Walensky, booster shots could be available to all adults as early as this weekend. read more |
| |
|---|
|
| | Spinal Muscular Atrophy: Overview & Outlook SMA is a rare and devastating disease. This 2-part series provides an overview of SMA and current therapies. It also provides an outlook on potential advancements that could affect the therapeutic and commercial landscapes. Download now. |
Top Stories By Nick Paul Taylor A “very important” part of Merck’s HIV strategy has come off the rails. Just months after talking up the importance of MK-8507, Merck has paused development of the asset in response to midphase data that also raised questions about the backbone of all the company’s planned HIV regimens. read more By Robert King The House passed a massive roughly $2 trillion infrastructure bill that includes drug price reforms, closes the Medicaid coverage gap and cuts DSH payments to hospitals in states that did not expand Medicaid. read more By Fraiser Kansteiner The pharma industry should emerge mostly unscathed if President Joseph Biden's Build Back Better bill makes its way into law. While the legislation would open the door to limited Medicare negotiations and cap price hikes at the rate of inflation, the cost to the industry and its pace of innovation would be minimal, a government analysis found. read more By Dave Muoio The American Medical Association, the American College of Physicians and dozens of other healthcare organizations and individual health experts called on employers to voluntarily implement OSHA's "reasonable and essential" vaccination requirements. read more By Conor Hale With a total footprint of about 4 feet by 3 feet, the cobas 5800 comes in a smaller package compared to the company’s high-throughput heavyweights in the cobas 6800 and 8800. read more By Fraiser Kansteiner Hungry for details on Pfizer's COVID-19 vaccine? Just file a FOIA request and wait until the U.S. Tricentennial in 2076. That's the schedule the FDA proposed in documents filed in a U.S. District Court this week. read more By Annalee Armstrong Just days ago, Bristol Myers was touting new data for the targeted heart drug mavacamten. Now, the Big Pharma has announced that the FDA has extended the decision date for the drug, which was nabbed through the $13 billion buyout of MyoKardia. read more By Ben Adams Enanta Pharmaceuticals is shutting down work on its oral hepatitis B program for EDP-721 after serious safety red flags were raised in a phase 1 study. read more By Eric Sagonowsky BioMarin has won the FDA's go-ahead for its next big launch. But the drug's arrival may be unwelcome news for those who've built a community out of living full lives with dwarfism. read more By Rebecca Torrence Trusted Health has raised $149 million to develop its staffing platform which matches nurses with open positions. The startup's AI-powered platform has already been deployed at more than 40 Mercy hospitals. read more By Conor Hale After picking up $200 million just over six months ago, Benchling isn’t sitting still. The cloud-based R&D platform developer collected another $100 million to help power its global expansion plans. read more By Arlene Weintraub A Brigham and Women's and MIT team discovered that T cells and cancer cells connect to each other with tiny tendrils, and that the cancer cells use those connections to suck energy from T cells. Inhibiting the formation of the tendrils could enhance immuno-oncology treatments, they suggested. read more | 